Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gedeon Richter Pledges New Markets For Teriparatide Biosimilar

Debuted In Three New Markets In Last 12 Months

Executive Summary

Gedeon Richter aims to continue the global roll-out of its teriparatide biosimilar, having enjoyed continued solid growth for the Forsteo rival during the first quarter.

You may also be interested in...



Generics Industry Fails To Match Last Year’s Growth In First Quarter

The generics industry struggled with the prior-year comparison as it saw an expected decline in revenues in the first quarter of 2021, driven by the global impact of the COVID-19 crisis. As a result, the performance of most companies fell short of the numbers reported in Q1 2020. However, a few managed to contradict the trend by reporting growth, either based on the launch of COVID-related drugs or performance in specific geographies. 

Gedeon Richter Pays $263.5m For Ex-US Rights To Janssen’s Evra

Hungarian firm Gedeon Richter is to expand further its sizeable women’s health portfolio after agreeing to acquire Janssen’s Evra (ethinyl estradiol/norelgestromin) transdermal patch outside of the US for more than a quarter of a billion dollars.

Gedeon Richter Spends Most On Biosimilar R&D

Hungary’s Gedeon Richter enjoyed “rapid sales growth” for its Terrosa teriparatide biosimilar in the first nine months of this year, justifying the firm’s continued advance into biosimilar development.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150971

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel